| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Upcoming multiple ascending dose data from SRP-1003 in DM1 and SRP-1001 in FSHD expected by year end; Company is actively preparing for Phase 3 development in both programs |
| 23 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
On September 23, 2026 (the “Effective Date”), Sarepta Therapeutics, Inc. (the “Company”), Sarepta Therapeutics Three, LLC (“Sarepta Three” and, together with the Company, “Sarepta”), REGENXBIO Inc. (“REGENXBIO”), the Trustees of the Univ... |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth |
| 27 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of July 24, 2026 by and between Sarepta Therapeutics, Inc. (the “Company”) and Michael Severino, M.D. (the “Executive”), and is effective as of July 28, 2026 (the “... |
| 04 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Exhibit A, which is incorporated by reference, defines certain terms used in the Plan and includes certain operational rules related to those terms. |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
Net product revenues for the first quarter 2026 totaled $330.5 million, consisting of $102.0 million of ELEVIDYS net product revenue and $228.6 million of PMO net product revenues |
| 25 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On February 25, 2026, Douglas Ingram notified Sarepta Therapeutics, Inc. (the “Company”) of his decision to retire as Chief Executive Officer by the end of 2026 or upon the appointment of his replacement. The Company has commenced a sear... |
| 25 Feb 2026 |
8-K: Results of Operations and Financial Condition
Net product revenues for the full year 2025 totaled $1,864.3 million, consisting of $965.6 million of PMO net product revenue and $898.7 million of ELEVIDYS net product revenue |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition
Preliminary ELEVIDYS net product revenue totaled $110.4 million for the fourth quarter and $898.7 million for full-year 2025 |
| 19 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
FIRST SUPPLEMENTAL INDENTURE, dated as of December 18, 2025, between SAREPTA THERAPEUTICS, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01 of the Base Indenture) and U.S. BANK TRUST COMPANY... |
| 11 Dec 2025 |
8-K: Unregistered Sales of Equity Securities; Other Events
CAMBRIDGE, Mass., December 11, 2025 (BUSINESS WIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has entered into separate, privately negotiated exchange ... |
| 08 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT CUSTOMARILY A... |
| 03 Nov 2025 |
8-K: Results of Operations and Financial Condition
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE |
| 29 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
INDENTURE dated as of August 28, 2025 between SAREPTA THERAPEUTICS, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking as... |
| 21 Aug 2025 |
8-K: Unregistered Sales of Equity Securities
On August 20, 2025, Sarepta Therapeutics, Inc. (the “Company”) entered into separate, privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its 1.25% Convertible Senior Notes due 2027 (the “Existing... |
| 13 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 21 Jul 2025 |
8-K: Other Events
On July 21, 2025, the Company announced that the U.S. Food and Drug Administration (“FDA”) has placed a clinical hold on the Company’s investigational gene therapy clinical trials for limb girdle muscular dystrophy (“LGMD”). The hold inc... |
| 16 Jul 2025 |
8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities +1 more
Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label |
| 06 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
WHEREAS, Sarepta Therapeutics, Inc. (the “Company”) previously adopted and approved the 2018 Equity Incentive Plan (the “Plan”); |
| 26 Feb 2025 |
8-K: Results of Operations and Financial Condition
Net product revenues for the fourth quarter 2024 totaled $638.2 million, a 75% increase over the same quarter of the prior year |
Loading...